Localization and Trafficking of Amyloid-β Protein Precursor and Secretases: Impact on Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 45, Issue 2, 2015, Pages 329-347

  Agostinho, Paula ^a,b   Pliássova, Anna ^a,b   Oliveira, Catarina R ^a,b   Cunha, Rodrigo A ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

ADAM10; amyloid ; A PP; A PP derived fragments; BACE1; presenilin; secretase

Indexed keywords

ADAM PROTEIN; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; ESTROGEN; GAMMA SECRETASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; SECRETASE; SULINDAC SULFIDE;

ALZHEIMER DISEASE; BRAIN; BRAIN FUNCTION; CELL MEMBRANE; CELLULAR DISTRIBUTION; CHRONIC STRESS; COGNITIVE DEFECT; GENE MUTATION; GLIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NERVE CELL; NERVE CELL PLASTICITY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REVIEW; SLEEP PATTERN; SYNAPSE; SYNAPTIC TRANSMISSION; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; HUMANS; PROTEIN TRANSPORT;

EID: 84925344255     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142730     Document Type: Review

References (197)

1. Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, Jonsson L, Khachaturian AS, Kramberger M (2014) Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria. J Intern Med 275, 304-316.
2. Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 21, 479-505.
3. St George-Hyslop PH (2000) Molecular genetics of Alzheimer's disease. Biol Psychiatry 47, 183-199.
4. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
5. Solomon A, Kivipelto M, Soininen H (2013) Prevention of Alzheimer's disease: moving backward through the lifespan. J Alzheimers Dis 33(Suppl 1), S465-S469.
6. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM (2011) Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 3, 89ra57.
7. Grimm MO, Zimmer VC, Lehmann J, Grimm HS, Hartmann T (2013) The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease. Biomed Res Int 2013, 814390
8. Petersen RC (2009) Early diagnosis of Alzheimer's disease: is MCI too late? Curr Alzheimer Res 6, 324-330.
9. Alzheimer A (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr Psych Gerichtl Med 64, 146-148.
10. Allsop D, Landon M, Kidd M (1983) The isolation and amino acid composition of senile plaque core protein. Brain Res 259, 348-352.
11. Turner PR, O'Connor K, Tate WP, Abraham WC (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70, 1-32.
12. Zhang H, Ma Q, Zhang YW, Xu H (2012) Proteolytic processing of Alzheimer's beta-amyloid precursor protein. J Neurochem 120, 9-21.
13. Lansbury PT Jr. (1997) Structural neurology: are seeds at the root of neuronal degeneration?. Neuron 19, 1151-1154.
14. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10, 698-712.
15. Agostinho P, Cunha RA, Oliveira C (2010) Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des 1, 2766-2778.
16. Zhang YW, Thompson R, Zhang H, Xu H (2011) APP processing in Alzheimer's disease. Mol Brain 4, 3.
17. Mucke L, Selkoe DJ (2012) Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2, a006338.
18. Wang J, Dickson DW, Trojanowski JQ, Lee VM (1999) The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158, 328-337.
19. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta-peptide in the brain andcognitive decline. JAMA 283, 1571-1577.
20. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
21. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
22. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
23. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
24. Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH (2010) Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci 30, 14946-14954.
25. Terry RD (2000) Cell death or synaptic loss in Alzheimer disease. J Neuropathol Exp Neurol 59, 1118-1119.
26. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks DJ (2007) Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68, 501-508.
27. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, Kemppainen N, Någren K, Kim BC, Tsui W, de Leon MJ (2008) Regional analysis of FDG and PIBPET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35, 2169-21681.
28. Scheff SW, Price DA (2003) Synaptic pathology in Alzheimer's disease: a reviewof ultrastructural studies. Neurobiol Aging 24, 1029-1046.
29. McGowan E, Eriksen J, Hutton M (2006) A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 22, 281-289.
30. Abbott A (2008) Neuroscience: The plaque plan. Nature 456, 161-164.
31. Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 110, 1129-1134.
32. Schnabel J (2009) Alzheimer's theory makes a splash. Nature 459, 310.
33. Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW (2009) Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci U S A 106, 18367-18372.
34. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457, 981-989.
35. O'Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 34, 185-204.
36. Gralle M, Ferreira ST (2007) Structure and functions of the human amyloid precursor protein: the whole is more than the sum of its parts. Prog Neurobiol 82, 11-32.
37. Zheng H, Koo EH (2011) Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener 6, 27.
38. Shariati SA, De Strooper B (2013) Redundancy and divergence in the amyloid precursor protein family. FEBS Lett 587, 2036-2045.
39. Korte M, Herrmann U, Zhang X, Draguhn A (2012) The role of APP and APLP for synaptic transmission, plasticity, and network function: lessons from genetic mouse models. Exp Brain Res 217, 435-440.
40. Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, Ring S, D'Adamio L, Shen J, Müller U, St George Hyslop P, Checler F (2005) Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron 4, 541-554.
41. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283, 29615-29619.
42. Cappai R (2014) Making sense of the amyloid precursor protein: its tail tells an interesting tale. J Neurochem 130, 325-327.
43. Belyaev ND, Kellett KA, Beckett C, Makova NZ, Revett TJ, Nalivaeva NN, Hooper NM, Turner AJ (2010) The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a beta-secretase-dependent pathway. J Biol Chem 285, 41443-41454.
44. Kitazume S, Tachida Y, Kato M, Yamaguchi Y, Honda T, Hashimoto Y, Wada Y, Saito T, Iwata N, Saido T, Taniguchi N (2010) Brain endothelial cells produce amyloid β from amyloid precursor protein 770 and preferentially secrete the O-glycosylated form. J Biol Chem 285, 40097-40103.
45. Davis S, Laroche S (2003) What can rodent models tell us about cognitive decline in Alzheimer's disease?. Mol Neurobiol 27, 249-276.
46. Petronis A (1999) Alzheimer's disease and down syndrome: from meiosis to dementia. Exp Neurol 158, 403-413.
47. Aydin D, Weyer SW, Müller UC (2012) Functions of the APP gene family in the nervous system: insights from mouse models. Exp Brain Res 217, 423-434.
48. Soba P, Eggert S, Wagner K, Zentgraf H, Siehl K, Kreger S, Löwer A, Langer A, Merdes G, Paro R, Masters CL, Müller U, Kins S, Beyreuther K (2005) Homo- and heterodimerization of APP family members promotes intercellular adhesion. EMBO J 24, 3624-3634.
49. Nalivaeva NN, Turner AJ (2013) The amyloid precursor protein: a biochemical enigma in brain development, function and disease. FEBS Lett 587, 2046-2054.
50. Octave JN, Pierrot N, Santos S, Nalivaeva NN, Turner AJ (2013) From synaptic spines to nuclear signaling: nuclear and synaptic actions of the amyloid precursor protein. J Neurochem 126, 183-190.
51. Kedikian G, Heredia F, Salvador VR, Raimunda D, Isoardi N, Heredia L, Lorenzo A (2010) Secreted amyloid precursor protein and holo-APP bind amyloid beta through distinct domains eliciting different toxic responses on hippocampal neurons. J Neurosci Res 88, 1795-1803.
52. Lorenzo A, Yuan M, Zhang Z, Paganetti PA, Sturchler-Pierrat C, Staufenbiel M, Mautino J, Vigo FS, Sommer B, Yankner BA (2000) Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat Neurosci 3, 460-464.
53. Ho A, Sudhof TC (2004) Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage. Proc Natl Acad Sci U S A 101, 2548-2553.
54. Taru H, Kirino Y, Suzuki T (2002) Differential roles of JIP scaffold proteins in the modulation of amyloid precursor protein metabolism. J Biol Chem 277, 27567-27574.
55. Wang Y, Zhang M, Moon C, Hu Q, Wang B, Martin G, Sun Z, Wang H (2009) The APP-interacting protein FE65 is required for hippocampus dependent learning and long-term potentiation. Learn Mem 16, 537-544.
56. Bignante EA, Heredia F, Morfini G, Lorenzo A (2013) Amyloid β precursor protein as a molecular target for amyloid β-induced neuronal degeneration in Alzheimer's disease. Neurobiol Aging 34, 2525-2537.
57. Chasseigneaux S, Allinquant B (2012) Functions of Aβ, sAPPα and sAPPβ: similarities and differences. J Neurochem 120(Suppl 1), 99-108.
58. De Strooper B, Annaert W (2000) Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 113, 1857-1870.
59. Owen DJ, Collins BM (2010)Vesicle transport: a new player in APP trafficking. Curr Biol 20, R413-R415.
60. Haass C, Kaether C, Thinakaran G, Sisodia S (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2, a006270.
61. Marquez-Sterling NR, Lo ACY, Sisodia SS, Koo EH (1997) Trafficking of cell-surface beta-amyloid precursor protein: Evidence that a sorting intermediate participates in synaptic vesicle recycling. J Neurosci 17, 140-151.
62. Claeysen S, Cochet M, Donneger R, Dumuis A, Bockaert J, Giannoni P (2012) Alzheimer culprits: cellular crossroads and interplay. Cell Signal 24, 1831-1840.
63. Sabo SL, Ikin AF, Buxbaum JD, Greengard P (2001) The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement. J Cell Biol 153, 1403-1414.
64. King GD, Scott Turner R: (2004) Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk? Exp Neurol 185, 208-219.
65. Jiang S, Li Y, Zhang X, Bu G, Xu H, Zhang YW (2014) Trafficking regulation of proteins in Alzheimer's disease. Mol Neurodegener 9, 6.
66. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2, a006312.
67. Cai D, Leem JY, Greenfield JP, Wang P, Kim BS, Wang R, Lopes KO, Kim SH, Zheng H, Greengard P, Sisodia SS, Thinakaran G, Xu H (2003) Presenilin-1 regulates intracellular trafficking and cell surface delivery of beta-amyloid precursor protein. J Biol Chem 278, 3446-3454.
68. Zhang C, Wu B, Beglopoulos V, Wines-Samuelson M, Zhang D, Dragatsis I, Südhof TC, Shen J (2009) Presenilins are essential for regulating neurotransmitter release. Nature 460, 632-636.
69. Matsushima T, Saito Y, Elliott JI, Iijima-Ando K, Nishimura M, Kimura N, Hata S, Yamamoto T, Nakaya T, Suzuki T (2012) Membrane-microdomain localization of amyloid β-precursor protein (APP) C-terminal fragments is regulated by phosphorylation of the cytoplasmic Thr668 residue. J Biol Chem 287, 19715-19724.
70. Schedin-Weiss S,Winblad B, Tjernberg LO (2014) The role of protein glycosylation in Alzheimer disease. FEBS J 281, 46-62.
71. Santos SF, Tasiaux B, Sindic C, Octave JN (2011) Inhibition of neuronal calcium oscillations by cell surface APP phosphorylated on T668. Neurobiol Aging 32, 2308-2313.
72. Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL (1990) Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci U S A 7, 1561-1565.
73. Gouras GK, Willén K, Faideau M (2014) The inside-out amyloid hypothesis and synapse pathology in Alzheimer's disease. Neurodegener Dis 13, 142-146.
74. Lazarov O, Morfini GA, Lee EB, Farah MH, Szodorai A, DeBoer SR, Koliatsos VE, Kins S, Lee VM, Wong PC, Price DL, Brady ST, Sisodia SS (2005) Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. J Neurosci 25, 2386-23895.
75. Giuffrida ML, Caraci F, De Bona P, Pappalardo G, Nicoletti F, Rizzarelli E, Copani A (2010) The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology. Rev Neurosci 21, 83-93.
76. Beckett C, Nalivaeva NN, Belyaev ND, Turner AJ (2012) Nuclear signalling by membrane protein intracellular domains: the AICD enigma. Cell Signal 24, 402-409.
77. Kerridge C, Belyaev ND, Nalivaeva NN, Turner AJ (2014) The Aβ-clearance protein transthyretin, like neprilysin, is epigenetically regulated by the amyloid precursor protein intracellular domain. J Neurochem 130, 419-431.
78. Grimm MO, Rothhaar TL, Hartmann T (2012) The role of APP proteolytic processing in lipid metabolism. Exp Brain Res 217, 365-375.
79. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 95, 6460-6464.
80. Pierrot N, Tyteca D, D'auria L, Dewachter I, Gailly P, Hendrickx A, Tasiaux B, Haylani LE, Muls N, N'kuli F, Laquerrière A, Demoulin JB, Campion D, Brion JP, Courtoy PJ, Kienlen-Campard P, Octave JN (2013) Amyloid precursor protein controls cholesterol turnover needed for neuronal activity. EMBO Mol Med 5, 608-625.
81. Fabelo N, Martín V, Marín R, Moreno D, Ferrer I, Díaz M (2014) Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimer's disease and facilitates APP/BACE1 interactions. Neurobiol Aging 35, 1801-1812.
82. Deuss M, Reiss K, Hartmann D (2008) Part-time alpha-secretases: the functional biology of ADAM 9, 10 and 17. Curr Alzheimer Res 5, 187-201.
83. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME (2008) A soluble form of the receptor for advanced glycation end-products (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22, 3716-3727.
84. Groot AJ, Habets R, Yahyanejad S, Hodin CM, Reiss K, Saftig P, Theys J, Vooijs M (2014) Regulated proteolysis of NOTCH2 and NOTCH3 receptors by A-Disintegrin-And-Metalloproteinase (ADAM) 10 and presenilins. Mol Cell Biol 34, 2822-2832.
85. Nunan J, Small DH (2000) Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett 483, 6-10.
86. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF (2010) ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 29, 3020-3032.
87. Jorissen E, Prox J, Bernreuther C, Weber S, Schwanbeck R, Serneels L, Snellinx A, Craessaerts K, Thathiah A, Tesseur I, Bartsch U, Weskamp G, Blobel CP, Glatzel M, De Strooper B, Saftig P (2010) The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci 30, 4833-4844.
88. Endres K, Fahrenholz F (2010) Upregulation of the alpha-secretase ADAM10-risk or reason for hope?. FEBS J 277, 1585-1596.
89. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A 96, 3922-3927.
90. Marcello E, Saraceno C, Musardo S, Vara H, de la Fuente AG, Pelucchi S, Di Marino D, Borroni B, Tramontano A, Pérez-Otaño I, Padovani A, Giustetto M, Gardoni F, Di Luca M (2013) Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer's disease. J Clin Invest 123, 2523-2538.
91. Marcello E, Epis R, Saraceno C, Gardoni F, Borroni B, Cattabeni F, Padovani A, Di Luca M (2012) SAP97-mediated local trafficking is altered in Alzheimer disease patients' hippocampus. Neurobiol Aging 33, 422.e1-10.
92. Seals DF, Courtneidge SA (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17, 7-30.
93. Epis R, Marcello E, Gardoni F, Vastagh C, Malinverno M, Balducci C, Colombo A, Borroni B, Vara H, Dell'Agli M, Cattabeni F, Giustetto M, Borsello T, Forloni G, Padovani A, Di Luca M (2010) Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease. Brain 133, 3323-3335.
94. Suh J, Choi SH, Romano DM, Gannon MA, Lesinski AN, Kim DY, Tanzi RE (2013) ADAM10 missense mutations potentiate β-amyloid accumulation by impairing prodomain chaperone function. Neuron 80, 385-401.
95. Postina R (2012) Activation of α-secretase cleavage. J Neurochem 120, 46-54.
96. Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, Lichtenthaler SF (2014) Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem 130, 4-28.
97. Bennett BD, Denis P, Haniu M, Teplow DB, Kahn S, Louis JC, Citron M, Vassar R (2000) A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's beta-secretase. J Biol Chem 275, 37712-37717.
98. Stockley JH, O'Neill C (2007) The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain. Biochem Soc Trans 35(Pt 3), 574-576.
99. Cole SL, Vassar R (2008) The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. J Biol Chem 283, 29621-29625.
100. Vassar R (2001) The beta-secretase, BACE: a prime drug target for Alzheimer's disease. J Mol Neurosci 17, 157-170.
101. Huse JT, Liu K, Pijak DS, Carlin D, Lee VM, Doms RW (2002) Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. J Biol Chem 9, 16278-16284.
102. Cisse M, Mucke L (2009) Alzheimer's disease: A prion protein connection. Nature 457, 1090-1091.
103. Griffiths HH, Whitehouse IJ, Baybutt H, Brown D, Kellett KA, Jackson CD, Turner AJ, Piccardo P, Manson JC, Hooper NM (2011) Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein. J Biol Chem 286, 33489-33500.
104. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM (2012) Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 15, 1227-1235.
105. Whitehouse IJ, Miners JS, Glennon EB, Kehoe PG, Love S, Kellett KA, Hooper NM (2013) Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-β levels and Braak stage. PLoS One 8, e59554.
106. Wahle T, Thal DR, Sastre M, Rentmeister A, Bogdanovic N, Famulok M, Heneka MT, Walter J (2006) GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide. J Neurosci 26, 12838-12846.
107. Das U, Scott DA, Ganguly A, Koo EH, Tang Y, Roy S (2013) Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. Neuron 9, 447-460.
108. Christensen DZ, Kraus SL, Flohr A, Cotel MC, Wirths O, Bayer TA (2008) Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol 116, 647-655.
109. Capetillo-Zarate E, Gracia L, Tampellini D, Gouras GK (2012) Intraneuronal Aβ accumulation, amyloid plaques, and synapse pathology in Alzheimer's disease. Neurodegener Dis 10, 56-59.
110. Schneider A, Rajendran L, Honsho M, Gralle M, Donnert G, Wouters F, Hell SW, Simons M (2008) Flotillin-dependent clustering of the amyloid precursor proteinregulates its endocytosis and amyloidogenic processing in neurons. J Neurosci 28, 2874-2882.
111. Prabhu Y, Burgos PV, Schindler C, Farias GG, Magadan JG, Bonifacino JS (2012) Adaptor protein 2-mediated endocytosis of the beta-secretase BACE1 is dispensable for amyloid precursor protein processing. Mol Biol Cell 23, 2339-2351.
112. Sannerud R, Declerck I, Peric A, Raemaekers T, Menendez G, Zhou L, Veerle B, Coen K, Munck S, De Strooper B, Schiavo G, Annaert W (2011) ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating theendosomal sorting of BACE1. Proc Natl Acad Sci U S A 108, E559-E568.
113. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 9, 233-234.
114. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37, 925-937.
115. Wang H, Song L, Lee A, Laird F, Wong PC, Lee HK (2010) Mossy fiber long-term potentiation deficits in BACE1 knock-outs can be rescued by activation of alpha7 nicotinic acetylcholine receptors. J Neurosci 30, 13808-13813.
116. Wang H, Megill A, Wong PC, Kirkwood A, Lee HK (2014) Postsynaptic target specific synaptic dysfunctions in the CA3 area of BACE1 knockout mice. PLoS One 9, e92279.
117. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R (2006) Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9, 1520-1525.
118. Hartlage-Rübsamen M, Zeitschel U, Apelt J, Gärtner U, Franke H, Stahl T, Günther A, Schliebs R, Penkowa M, Bigl V, Rossner S (2003) Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Glia 41, 169-179.
119. Rossner S, Lange-Dohna C, Zeitschel U, Perez-Polo JR (2005) Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. J Neurochem 92, 226-234.
120. Tamagno E, Guglielmotto M, Monteleone D, Tabaton M (2012) Amyloid-β production: major link between oxidative stress and BACE1. Neurotox Res 22, 208-219.
121. Bulbarelli A, Lonati E, Brambilla A, Orlando A, Cazzaniga E, Piazza F, Ferrarese C, Masserini M, Sancini G (2012) Aβ42 production in brain capillary endothelial cells after oxygen and glucose deprivation. Mol Cell Neurosci 49, 415-422.
122. Plácido AI, Oliveira CR, Moreira PI, Pereira CM (2014) Enhanced amyloidogenic processing of amyloid precursor protein and cell death under prolonged endoplasmic reticulum stress in brain endothelial cells. Mol Neurobiol, doi: 10.1007/s12035-014-8819-1.
123. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59, 1381-1389.
124. Evin G, Barakat A, Masters CL (2010) BACE: Therapeutic target and potential biomarker for Alzheimer's disease. Int J Biochem Cell Biol 42, 1923-1936.
125. Tan. J, Evin G (2012) β-site APP-cleaving enzyme 1 trafficking and Alzheimer's disease pathogenesis. J Neurochem 120, 869-880.
126. Zhao. J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R, Binder L, Vassar R (2007) Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci 27, 3639-36349.
127. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S (2007) Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J Biol Chem 282, 26326-26334.
128. Haass C, Selkoe DJ (1993) Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide. Cell 75, 1039-1042.
129. De Strooper B (2003) Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron 38, 9-12.
130. De Strooper B, Iwatsubo T, Wolfe MS (2012) Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb Perspect Med 2, a006304.
131. Laudon H, Hansson EM, Melén K, Bergman A, Farmery MR, Winblad B, Lendahl U, von Heijne G, Näslund J (2005) A nine-transmembrane domain topology for presenilin 1. J Biol Chem 280, 35352-35360.
132. Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T (2003) The role of presenilin cofactors in the gamma-secretase complex. Nature 422, 438-441.
133. Dries DR, Yu G (2008) Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease. Curr Alzheimer Res 5, 132-146.
134. Liu Y, Zhang YW, Wang X, Zhang H, You X, Liao FF, Xu H (2009) Intracellular trafficking of presenilin 1 is regulated by beta-amyloid precursor protein and phospholipase D1. J Biol Chem 284, 12145-12152.
135. Li T, Ma G, Cai H, Price DL, Wong PC (2003) Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals. J Neurosci 23, 3272-3277.
136. Gandy S, Zhang YW, Ikin A, Schmidt SD, Bogush A, Levy E, Sheffield R, Nixon RA, Liao FF, Mathews PM, Xu H, Ehrlich ME (2007) Alzheimer's presenilin 1 modulates sorting of APP and its carboxyl-terminal fragments in cerebral neurons in vivo. J Neurochem 102, 619-626.
137. Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS (2001) Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 414, 643-648.
138. Lazarov O, Lee M, Peterson DA, Sisodia SS (2002) Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 22, 9785-9793.
139. Hébert SS, Bourdages V, Godin C, Ferland M, Carreau M, Lévesque G (2003) Presenilin-1 interacts directly with the beta-site amyloid protein precursor cleaving enzyme (BACE1). Neurobiol Dis 13, 238-245.
140. Wu J, Petralia RS, Kurushima H, Patel H, Jung MY, Volk L, Chowdhury S, Shepherd JD, Dehoff M, Li Y, Kuhl D, Huganir RL, Price DL, Scannevin R, Troncoso JC, Wong PC, Worley PF (2011) Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent β-amyloid generation. Cell 147, 615-628.
141. Nadler Y, Alexandrovich A, Grigoriadis N, Hartmann T, Rao KS, Shohami E, Stein R (2008) Increased expression of the gamma-secretase components presenilin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury. Glia 56, 552-567.
142. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R (1999) A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518-522.
143. De Strooper B, Iwatsubo T, Wolfe MS (2012) Presenilins and γ-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med 2, a006304.
144. Haass C, Selkoe DJ (1998) Alzheimer's disease.Atechnical KO of amyloid-beta peptide. Nature 391, 339-340.
145. Struhl G, Greenwald I (1999) Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 398, 522-525.
146. LaVoie MJ, Selkoe DJ (2003) The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem 278, 34427-34437.
147. Costa RM, Drew C, Silva AJ (2005) Notch to remember. Trends Neurosci 28, 429-435.
148. Nakayama K, Nagase H, Koh CS, Ohkawara T (2011) γ-Secretase-regulated mechanisms similar to notch signaling may play a role in signaling events, including APP signaling, which leads to Alzheimer's disease. Cell Mol Neurobiol 31, 887-900.
149. Nakayama K, Ohkawara T, Hiratochi M, Koh CS, Nagase H (2008) The intracellular domain of amyloid precursor protein induces neuron-specific apoptosis. Neurosci Lett 444, 127-131.
150. Pintchovski SA, Schenk DB, Basi GS (2013) Evidence that enzyme processivity mediates differential Aβ production by PS1 and PS2. Curr Alzheimer Res 10, 4-10.
151. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, 3rd, Kandel ER, Duff K, Kirkwood A, Shen J (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42, 23-36.
152. Feng R, Wang H, Wang J, Shrom D, Zeng X, Tsien JZ (2004) Forebrain degeneration and ventricle enlargement caused by double knockout of Alzheimer's presenilin-1 and presenilin-2. Proc Natl Acad Sci U S A 101, 8162-8167.
153. Zhang XM, Cai Y, Xiong K, Cai H, Luo XG, Feng JC, Clough RW, Struble RG, Patrylo PR, Yan XX (2009) Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Eur J Neurosci 30, 2271-2283.
154. Auffret A, Gautheron V, Repici M, Kraftsik R, Mount HT, Mariani J, Rovira C (2009) Age-dependent impairment of spine morphology and synaptic plasticity in hippocampal CA1 neurons of a presenilin 1 transgenic mouse model of Alzheimer's disease. J Neurosci 29, 10144-10152.
155. Jung CK, Fuhrmann M, Honarnejad K, Van Leuven F, Herms J (2011) Role of presenilin 1 in structural plasticity of cortical dendritic spines in vivo. J Neurochem 119, 1064-1073.
156. Wang Y, Tang XC, Zhang HY (2012) Huperzine A alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APPswe/PS1dE9 transgenic mice. J Neurosci Res 90, 508-517.
157. Wolfe MS (2008) Gamma-secretase inhibition and modulation for Alzheimer's disease. Curr Alzheimer Res 5, 158-164.
158. Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L (2013) γ-Secretase inhibitors and modulators. Biochim Biophys Acta 1828, 2898-2890.
159. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216.
160. Xia W, Wong ST, Hanlon E, Morin P (2012) γ-Secretase modulator in Alzheimer's disease: shifting the end. J Alzheimers Dis 31, 685-696.
161. Araque A, Parpura V, Sanzgiri RP, Haydon PG (1999) Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci 22, 208-215.
162. Halassa MM, Haydon PG (2010) Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu Rev Physiol 72, 335-355.
163. Santello M, Calì C, Bezzi P (2012) Gliotransmission and the tripartite synapse. Adv Exp Med Biol 970, 307-331.
164. Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, Joung J, Foo LC, Thompson A, Chen C, Smith SJ, Barres BA (2013) Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature 504, 394-400.
165. Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, Alberini CM (2011) Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 144, 810-823.
166. Lima A, Sardinha VM, Oliveira AF, Reis M, Mota C, Silva MA, Marques F, Cerqueira JJ, Pinto L, Sousa N, Oliveira JF (2014) Astrocyte pathology in the prefrontal cortex impairs the cognitive function of rats. Mol Psychiatry 19, 834-841.
167. Kulijewicz-Nawrot M, Verkhratsky A, Chvátal A, SykováE, Rodríguez JJ (2012) Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer's disease. J Anat 221, 252-262.
168. Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, Bae JY, Kim T, Lee J, Chun H, Park HJ, Lee DY, Hong J, Kim HY, Oh SJ, Park SJ, Lee H, Yoon BE, Kim Y, Jeong Y, Shim I, Bae YC, Cho J, Kowall NW, Ryu H, Hwang E, Kim D, Lee CJ (2014) GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. Nat Med 20, 886-896.
169. Matos M, Augusto E, Machado NJ, dos Santos-Rodrigues A, Cunha RA, Agostinho P (2012) Astrocytic adenosine A2A receptors control the amyloid-β peptide-induced decrease of glutamate uptake. J Alzheimers Dis 31, 555-567.
170. Matos M, Augusto E, Oliveira CR, Agostinho P (2008) Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience 156, 898-891.
171. Bechtholt-Gompf AJ, Walther HV, Adams MA, Carlezon WA Jr, Ongür D, Cohen BM (2010) Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory. Neuropsychopharmacology 35, 2049-2059.
172. Rodrigues DI, Gutierres J, Pliássova A, Oliveira CR, Cunha RA, Agostinho P (2014) Synaptic and sub-synaptic localization of amyloid-β protein precursor in the rat hippocampus. J Alzheimers Dis 40, 981-992.
173. Bell KF, de Kort GJ, Steggerda S, Shigemoto R, Ribeiro-da-Silva A, Cuello AC (2003) Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology. Neurosci Lett 35, 143-147.
174. Sokolow S, Henkins KM, Bilousova T, Miller CA, Vinters HV, Poon W, Cole GM, Gylys KH (2012) AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly. Neurobiol Aging 33, 1545-1555.
175. Canas PM, Simões AP, Rodrigues RJ, Cunha RA (2014) Predominant loss of glutamatergic terminal markers in a β-amyloid peptide model of Alzheimer's disease. Neuropharmacology 76 Pt A 51-56.
176. Bell KF, Ducatenzeiler A, Ribeiro-da-Silva A, Duff K, Bennett DA, Cuello AC (2006) The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol Aging 27, 1644-1657.
177. Garcia-Marin V, Blazquez-Llorca L, Rodriguez JR, Boluda S, Muntane G, Ferrer I, Defelipe J (2009) Diminished perisomatic GABAergic terminals on cortical neuronsadjacent to amyloid plaques. Front Neuroanat 20, 3-28.
178. Zhao J, O'Connor T, Vassar R (2011) The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis. J Neuroinflammation 8, 150.
179. Thal DR (2012) The role of astrocytes in amyloid β-protein toxicity and clearance. Exp Neurol 236, 1-5.
180. Bandyopadhyay S, Hartley DM, Cahill CM, Lahiri DK, Chattopadhyay N, Rogers JT (2006) Interleukin-1alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAPkinase. J Neurosci Res 84, 106-118.
181. Goddard DR, Bunning RA, Woodroofe MN (2001) Astrocyte and endothelial cell expression of ADAM 17 (TACE) in adult human CNS. Glia 34, 267-271.
182. Durand D, Carniglia L, Beauquis J, Caruso C, Saravia F, Lasaga M (2014) Astroglial mGlu3 receptors promote alpha-secretase-mediated amyloid precursor protein cleavage. Neuropharmacology 79, 180-189.
183. Nizzari M, Venezia V, Bianchini P, Caorsi V, Diaspro A, Repetto E, Thellung S, Corsaro A, Carlo P, Schettini G, Florio T, Russo C (2007) Amyloid precursor protein and Presenilin 1 interaction studied by FRET in human H4 cells. Ann N Y Acad Sci 1096, 249-257.
184. Zhang QG, Wang RM, Scott E, Han D, Dong Y, Tu JY, Yang F, Reddy Sareddy G, Vadlamudi RK, Brann DW (2013) Hypersensitivity of the hippocampal CA3 region to stressinduced neurodegeneration and amyloidogenesis in a rat model of surgical menopause. Brain 136, 1432-1445.
185. Dobrowolska JA, Kasten T, Huang Y, Benzinger TL, Sigurdson W, Ovod V, Morris JC, Bateman RJ (2014) Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLoS One 9, e89998.
186. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O'Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard M (2013) Sleep drives metabolite clearance from the adult brain. Science 342, 373-377.
187. Tran TT, Srivareerat M, Alhaider IA, Alkadhi KA (2011) Chronic psychosocial stress enhances long-term depression in a subthreshold amyloid-beta rat model of Alzheimer's disease. J Neurochem 119, 408-416.
188. Alkadhi KA (2012) Chronic psychosocial stress exposes Alzheimer's disease phenotype in a novel at-risk model. Front Biosci 4, 214-229.
189. Sotiropoulos I, Catania C, Pinto LG, Silva R, Pollerberg GE, Takashima A, Sousa N, Almeida OF (2011) Stress acts cumulatively to precipitate Alzheimer's disease-like tau pathology and cognitive deficits. J Neurosci 31, 7840-7847.
190. Devi L, Alldred MJ, Ginsberg SD, Ohno M (2012) Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer's disease. PLoS One 7, e32792.
191. Wang Y, Li M, Tang J, Song M, Xu X, Xiong J, Li J, Bai Y (2011) Glucocorticoids facilitate astrocytic amyloid-β peptide deposition by increasing the expression of APP and BACE1 and decreasing the expression of amyloid-β-degrading proteases. Endocrinology 152, 2704-2715.
192. de la Monte SM, Tong M (2014) Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol 88, 548-559.
193. Moreira PI (2012) Alzheimer's disease and diabetes: an integrative viewof the role of mitochondria, oxidative stress, and insulin. J Alzheimers Dis 30(Suppl 2), S199-S215.
194. Devi L, Alldred MJ, Ginsberg SD, Ohno M (2010) Sex- and brain region-specific acceleration of β-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. Mol Brain 3, 34.
195. Xiong K, Clough RW, Luo XG, Struble RG, Li YM, Yan XX (2007) [3H]-L-685,458 as aradiotracer that maps gamma-secretase complex in the rat brain: relevance to Abeta genesis and presence of active presenilin-1 components. Brain Res 1157, 81-91.
196. Lindauer U, Gethmann J, Kühl M, Kohl-Bareis M, Dirnagl U (2003) Neuronal activity-induced changes of local cerebral microvascular blood oxygenation in the rat: effect of systemic hyperoxia or hypoxia. Brain Res 975, 135-140.
197. Cai Y, Xiong K, Zhang XM, Cai H, Luo XG, Feng JC, Clough RW, Struble RG, Patrylo PR, Chu Y, Kordower JH, Yan XX (2010) β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation. Eur J Neurosci 32, 1223-1238.